Projects - Worldpathol

2023

Project TRIVAC (EIC Accelerator)

Controlling Major Diseases in Swine through Effective Vaccination.

Step 1 of the EIC Accelerator program GO. Step 2 under submission.

Project EMRA (Phase II)

New technological solution for the treatment and valorisation of slurry (phase 2).

Patent P35259EP00: Recycling Modular Station (EMRA)

Project PEPDERMA (Phase I)

Development of artificial inclusion bodies for the controlled release of mimetic peptides.

Project PLAVAC

Design and optimization of a COLI platform for the rapid and universal production of autogenous APIs.

Project FEEDPIG (Phase I)

EMRA: Analysis of the nutritional potential of the circular system for the management and conversion of slurry.

Project BIORREME23 (Phase I)

Research and development of a novel organic amendment for the recovery of burned soils.

2022

2

Project TRIVAC2022

New recombinant active ingredients for major pig diseases.

Project BELANCE22

Efficiency research of a supplementation system according to biotypes in interval sport.

Project EPIGEN2022

Epigenetics as a clinical prognostic factor in treatments against solar elastosis.

Project EOLIGA2022

New technological solution for the treatment and valorisation of slurry; Modular Waste Station of Aragon (EMRA).

Project VETPRRS222

New biotechnological preparation against porcine reproductive and respiratory syndrome.

Project NANOPORC22

New microencapsulation process of biological products for antibiotic premixes.

2021

Aragon’s Seal of Social Responsibility

We obtain the RSA seal that certifies our full adherence and responsible compliance with all stakeholders.

Technological experimentation farm

The farm for technological experimentation is born where WORLPATHOL develops and tests products under strict 3R standards.

Project VEHICULA

New controlled release system for biotechnological active ingredients.

Project VACSUIS21

Development of the GMP VACSUIS antigen platform.

Project FEEDBACK21

New platform for veterinary autologous preventive medicine.

Project NATCOVID19

New therapeutic alternative against Covid19.

Project DIAGLAMP20

Development of a dual diagnostic kit for SARS-COV-2 and influenza based on LAMP technology.

2020

Homologation and certification

Worldpathol obtains Biosafety Level 3 registration for Aragon Goverment.

Seal of excellence

VACPOR© project was certified with the Seal of Excellence by the European Commission.

Health Center COVID 19

The community fight against the pandemic is reflected in WORLDPATHO through the new COVID 19 Health Center.

Project ANTICOV020: SARS-COV-2

Research into new stable recombinant fermentation vaccine panantigens.

ProjectCIRCOPOR20

Porcine circovirus type 2b: galenization and antigen immunization dynamics.

2019

Project VACSUIS

New vaccine against Haemophilus parasuis: Development of the antigen production platform.

Project VACPOR

New vaccine against porcine circovirus type 2b: Development of antigen production platform.

2017

Customized projects for leading laboratories.

We develop complete R&D projects by contract, integrating QbD validation and GMP-boarded proof of concept.

2016

Development of functional peptides

Recombinant biomimetic peptides based on proprietary fermentation platforms.

HYAWORLD

A new cross-linked hyaluronic acid based on recombinant technology.

2015

Autogenous Vaccines

With innovative technology to enhance the immune response.

2014

R&D Facilities at La Cartuja, Zaragoza

Fully equipped for cell culture, microbiology, chemical analysis, proteomics, molecular biology and preclinical.

VACSDC Development

The first recombinant polyvalent vaccine against lamb diarrheal syndrome.

2013

VACSUIS Drug & Discovery

New patented nonavalent recombinant vaccine against Glaesserella parasuis (Glässer’s disease).

2012

VACPOR Drug & Discovery

A highly innovative bivalent recombinant vaccine against porcine circovirus type 2.

2011

WORLDPATHOL was born!

Innovative Technology-Based Family Business (EIBT*) specialized in recombinant biotechnology.

We are a highly qualified team dedicated to comprehensive recombinant biotechnology R&D in continuous search of excellence.